Try our Advanced Search for more refined results

September 26, 2016

Vanda Pharmaceuticals Inc. v. Roxane Laboratories Inc.

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. July 16, 2018

    Don't Rethink OK'ing Fanapt Patent, Vanda Tells Fed. Circ.

    Vanda Pharmaceuticals Inc. has asked the Federal Circuit not to reconsider West-Ward Pharmaceuticals' challenge to a patent covering the schizophrenia drug Fanapt, saying the court rightly found that the medication was patent-eligible under the U.S. Supreme Court's Mayo test.

2 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!